Australia’s national medical research body has advised that puberty blockers remain appropriate for transgender children in certain circumstances, following a comprehensive review of international evidence.

The guidance issued by the commonwealth-funded National Health and Medical Research Council (NHMRC) comes after the federal government commissioned a review into the treatments last year. The directive contrasts with regional public hospital bans implemented by governments in Queensland and the Northern Territory.

The NHMRC's findings follow a year-long evaluation of global medical data regarding gender-affirming care for youths. The council concluded that conditional use of the medications is warranted under specific clinical conditions, highlighting a divergence between national medical research recommendations and certain state and territory hospital policies.